Highlights Newsletter 4

This newsletter presents you the following key sessions:

1. PODCAST with dr. Tapan Kadia about adding venetoclax to cladribine + low dose AraC alternating with
    5-azacytidine in older patients with newly diagnosed acute myeloid leukemia

2. Updated long-term data with tisagenlecleucel confirm sustained benefit in patients with relapsed/refractory
    diffuse large B-cell lymphoma

3. Increased risk for adverse outcomes in patients with haematologic malignancies and COVID-19 infection

4. Daratumumab induces deeper and longer responses in patients with newly diagnosed multiple myeloma

5. First-in-class STAMP inhibitor asciminib outperforms bosutinib in patients with chronic myeloid leukaemia,
    previously treated with at least two tyrosine kinase inhibitors